RTW Biotech Opportunities Ltd (LON:RTW), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, has noted an additional investment in the $165 million crossover financing of private portfolio company Windward Bio. Windward is a private, clinical-stage biotechnology company committed to improving outcomes for people living with serious immunological diseases. RTW Bio first invested in Windward’s Series A launch in January 2025 and is investing $1.7 million as part of this financing.
· $165 million crossover financing to advance clinical studies in asthma and COPD
· RTW Bio investing $1.7 million as part of the financing round
· As at 31 March 2026, Windward Bio represented 0.6% of the Company’s NAV
Lead program WIN378 is an antibody designed to treat asthma and chronic obstructive pulmonary disease (COPD). The drug has been engineered for an extended half-life, enabling twice-yearly subcutaneous dosing, a meaningful step forward from the monthly administration required by most current biologics. It is currently being evaluated in a Phase 2/3 asthma study, with initial readouts expected in the second half of 2026. If approved, WIN378 would be the first ultra long-acting anti-TSLP antibody available to patients.
As at 31 March 2026, Windward represented 0.6% of the Company’s NAV.
Rod Wong, CIO of RTW Investments, said, “We are pleased to further support Windward Bio as it advances a differentiated portfolio of long‑acting immunology therapies with the potential to meaningfully improve outcomes for patients. WIN378 has the profile we look for in a best-in-class asset: a well-validated target, a clear durability advantage over existing treatments, and compelling clinical trial data. This financing round will position the Windward team well to set a new standard of care for patients with asthma and COPD.”
